Project Grant R43CA275541
Award Date
9/20/23
Completion Date
8/31/24
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Awardee
Liquid Biodx LLC (NEXKNKCJEFD4)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The grant will fund the development of a novel liquid biopsy assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and prediction of NSCLC subtypes. The project aims to validate the performance of this new assay for detection of minimal...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an innovative circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of immunotherapy treatments in non-small cell lung cancer patients. The $990,771 award to Binary Genomics, Inc. over the 2-year project period from 09/2024 to 08/2026 will support advancing the company's epigenetic-based ctDNA detection approach...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
The National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,999,108 Project Grant to Orbit Genomics, Inc. for the "Development of a Lung Cancer Subtyping Diagnostic." The goal of this project is to create a highly sensitive and specific diagnostic test to accurately subtype lung cancer, which is critical for selecting the most effective treatment and reducing mortality. This new subtyping capability will be...
The federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is focused on developing noninvasive imaging and blood-based biomarkers to improve prediction of immunotherapy response and clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC). The $1,820,020 award, which runs from May 2024 to April 2029, will support research to: (1) create knowledge-guided radiomics and deep...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Detection and Diagnosis Research (CFDA 93.394), provides $554,653 to the Institute for Systems Biology (ISB) to develop and validate the "RareCyteFinder" toolkit. This label-free, genome-wide analysis platform aims to enable unbiased identification and comprehensive molecular profiling of rare disseminated tumor cells, including circulating tumor cells (CTCs) and isolated tumor...
This $600,534 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of Link Biosystems Inc.'s bioreactor technologies to efficiently generate large quantities of "immunocompetent tumoroid tissues" from patient tumor samples. These tumoroid tissues will enable enhanced preclinical screening of cancer therapeutics, including immunotherapies, biologics, and drug combinations, to identify optimal treatment regimens...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to Electronic Biosciences, Inc., a small biotechnology company in San Diego, CA. The funding will support the development of a novel nanopore-based sequencing approach to accurately characterize repetitive DNA sequences, which are challenging to analyze using current sequencing-by-synthesis technology. This capability will enable improved cancer...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000 to Onc.ai, Inc. to validate radiomics-based multi-modal predictive models for assessing response to PD-(L)1 immunotherapy in Stage IV non-small cell lung cancer patients. The key objectives are to: 1) prospectively validate the predictive models in a multi-institutional clinical study; 2) evaluate the models' performance characteristics...